Deal Library / Pharma BD Deal Intelligence

Biogen Inc. — Pharma Deals

The Pharma Closeout tracks 8 deals, $20.7B in disclosed deal value, 4 with a post-close Outcome Score for Biogen Inc..

Median Critic Score: 78  ·  Median Outcome Score: 60

Best outcome: Biogen Inc. / Reata Pharmaceuticals (73)  ·  Weakest outcome: Biogen Inc. / Bristol-Myers Squibb Company (15)

All 8 deals

• Biogen Inc. / Reata Pharmaceuticals — 2023 · $7.3B · Largely worked — most objectives met.
• Biogen Inc. / Human Immunology Biosciences — 2024 · $1.1B · Largely worked — most objectives met.
• Biogen Inc. / RayThera Inc. — 2026 · $1.0B · Mixed — partial payoff, real shortfalls.
• Biogen Inc. / Bristol-Myers Squibb Company — 2017 · $710M · Did not work — the deal failed to deliver.
• Biogen Inc. / Apellis Pharmaceuticals, Inc. — 2026 · $5.6B
• Biogen Inc. / Neomorph Inc. — 2024 · $1.4B
• Biogen Inc. / Sangamo Therapeutics, Inc. — 2020 · $2.7B
• Biogen Inc. / Nightstar Therapeutics plc — 2019 · $800M

← Deal Library  ·  Interactive search  ·  How we score deals